25 results about "EBV Infections" patented technology

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The present invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes Epstein-Barr virus gp42 protein and its application. The monoclonal antibody or its antigen-binding fragment has good binding activity with gp42 protein, has high affinity for gp42 protein, can specifically recognize natural gp42 protein expressed on the cell surface, can significantly inhibit EBV infection of B cells, and effectively inhibits cell membrane fusion. It can be used to detect the presence or level of gp42 protein in a sample, detect Epstein-Barr virus, diagnose diseases caused by Epstein-Barr virus infection, prevent Epstein-Barr virus infection, and / or treat and / or prevent diseases caused by Epstein-Barr virus infection.

The present disclosure provides antibodies, and antigen binding fragments thereof, which bind an extracellular domain region of an Epstein-Barr virus (EBV) membrane protein, and related nucleic acids, vectors, pharmaceutical compositions, cells, and methods of use thereof. The antibodies, and antigen binding fragments thereof, as described herein can find utility as therapeutic and diagnostic agents for EBV infections and EBV-mediated diseases or as research agents.

The invention provides an EBV susceptible 293T cell capable of simultaneously expressing an epidermal cell receptor EphA2 and a cleavage replication key protein RTA, and an EBV susceptible BJAB cell capable of simultaneously expressing a B cell receptor CD21 and a cleavage replication key protein ZTA, so that the infectivity of the cells on EBV is remarkably improved. The EBV infection titer of the cell line disclosed by the invention is more than three times that of normal control under the same condition. The EBV susceptible cells are of great significance to research of EBV infection mechanisms, screening of antiviral drugs and research and development of vaccines.

This invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes the Epstein-Barr virus (EBV) gp350 protein and its applications. This invention provides a monoclonal antibody against the EBV gp350 protein or its antigen-binding fragment, comprising 1A12 and 2E4, wherein 1A12 has a high affinity for the gp350 protein (KD(M) = 3.415E). ‑10 ), 2E4 has a high affinity for gp350 protein (KD(M) = 4.851E). ‑9 These two monoclonal antibodies or their antigen-binding fragments can significantly inhibit EBV infection of epithelial cells and B cells. They can be used to detect the presence or level of gp350 protein in samples, detect EBV, diagnose diseases caused by EBV infection, prevent EBV infection and / or treat and / or prevent diseases caused by EBV infection.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

This invention provides EBV-susceptible 293T cells that simultaneously express the epidermal cell receptor EphA2 and the key protein RTA for lysis and replication, and EBV-susceptible BJAB cells that simultaneously express the B cell receptor CD21 and the key protein ZTA for lysis and replication, significantly enhancing the infectivity of these cells for EBV. The EBV infection titer of the cell lines of this invention is more than three times that of the normal control under the same conditions. These EBV-susceptible cells are of great significance for studying the mechanism of EBV infection, screening antiviral drugs, and developing vaccines.

The invention discloses a probe for detecting EBV infected tissue, a kit and a detection method, and belongs to the technical field of virus detection, the key point of the technical scheme is that the probe for detecting the EBV infected tissue is an EBER-PNA probe, the sequence number is GCGACACATGTCTGC, the EBER-specific target probe and EBER in cells are hybridized, flow cytometry is combined, and the EBER-PNA probe can be used for detecting the EBV infected tissue. The kit is high in specificity, low in background and high in signal-to-noise ratio, the detection method is simple and accurate, EBER RNA expression and protein of the same cell can be efficiently detected, infected and non-infected EBV cell subsets can be recognized, and typing and function comparison are carried out.

Compositions and methods are provided for the detection of cell-mediated immunity to Epstein-Barr virus (EBV), including a method for detecting or confirming an EBV infection (e.g., a latent EBV infection) by contacting, in vitro, whole blood samples from subjects suspected to have an EBV infection with compositions comprising combinations of T-cell epitope-containing peptides derived from EBNA-1, EBNA-3A, and EBNA-3B proteins, and indirectly detecting EBV-specific activated T-cells by determining production of a T-cell response indication (e.g., interferon-γ) in response to stimulation by the peptides. Also disclosed are sample collection vessels comprising the peptide compositions as well as kits comprising the peptide composition for use in detecting an EBV infection (e.g., a latent EBV infection) in a subject. Further disclosed are vaccines comprising T-cell epitope-containing peptides derived from EBNA-3A, and EBNA-3B proteins and methods for stimulating T cell response using such vaccines.

Reconstructed Modified Vaccinia Ankara (rMVA) vectors configured to encode stable Epstein Bar Virus (EBV) glycoproteins gp42, gL, gH, gp350, and gB, compositions comprising the rMVA vectors, vaccines comprising the compositions, and methods of preventing EBV infection by administering the vaccines and eliciting an innate and humoral immune response.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The invention discloses a reagent and a kit for detecting EB (Epstein-Barr) virus infection and a method for detecting EB virus infected cell lineage, and belongs to the field of medical diagnosis. The technical problem to be solved by the invention is how to accurately locate different cell lineages of EBER + cells. The reagent for detecting EB virus infection disclosed by the invention contains an EBV probe and an antibody for marking a cell lineage, the sequence of the EBV probe is shown as SEQ ID No.1 and SEQ ID No.2, and the antibody for marking the cell lineage is a CD3 antibody, a CD20 antibody and / or a CD56 antibody. The reagent and the kit for detecting EB virus infection can be used for simultaneous marking of EBER genes and antigen proteins, accurate positioning of different cell lineages of EBER + cells is achieved, and cell lineage positioning of EB virus infection is further achieved.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody 5E9 for recognizing human R9AP protein and application thereof. The monoclonal antibody or antigen binding fragment thereof has high affinity to R9AP protein and can significantly inhibit EBV infection on epithelial cells and B cells. The antibody can be used for detecting the presence or level of R9AP protein in a sample, detecting diseases caused by high expression of R9AP, and preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The present invention relates to the technical field of antibodies. Disclosed are a monoclonal antibody 5E9 for recognizing a human R9AP and a use thereof. The monoclonal antibody or an antigen-binding fragment thereof has a high affinity to an R9AP and can significantly inhibit the infection of EB virus (EBV) on epithelial cells and B cells. The antibody can be used for detecting the presence or level of the R9AP in a sample, detecting diseases caused by high expression of the R9AP and preventing EBV infections and / or treating and / or preventing diseases caused by EBV infections.

Described herein are compositions and methods for treating or preventing EBV infection in a subject, and treating or preventing a disease or disorder caused by EBV infection in a subject.

Provided are a pharmaceutical composition comprising a delivery vehicle and at least two Epstein-Barr virus (EBV) antigen-encoding messenger ribonucleic acid (mRNA) constructs. Methods of treatment, methods of making, uses of the pharmaceutical composition, and pharmaceutical compositions comprising at least two or more EBV antigens are provided. All contemplate treating and preventing (i.e. reducing the likelihood of a symptom or a severity of a symptom of) EBV infections and EBV-associated diseases, such as infectious mononucleosis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

The present invention belongs to the field of antibody technology and discloses a monoclonal antibody 2B7 that recognizes the Epstein-Barr virus gp42 protein and its application. The monoclonal antibody or its antigen-binding fragment has good binding activity with the gp42 protein and has a high affinity for the gp42 protein (KD(M)=2.09E-12), can significantly inhibit EBV infection of epithelial cells and B cells, and can be used to detect the presence or level of gp42 protein in a sample, detect EBV, diagnose diseases caused by EBV infection, prevent EBV infection, and / or treat and / or prevent diseases caused by EBV infection.

Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.

The present invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes the gL protein of Epstein-Barr virus and its application. The monoclonal antibody or its antigen-binding fragment has good binding activity with the gL protein and / or the gHgL protein, has a high affinity for the gL protein and / or the gHgL protein, can specifically recognize the natural gL protein and / or the gHgL protein expressed on the cell surface, can significantly inhibit EBV infection of B cells and epithelial cells, and effectively inhibits cell membrane fusion. It can be used to detect the presence or level of the gL protein and / or the gHgL protein in a sample, detect Epstein-Barr virus, diagnose diseases caused by Epstein-Barr virus infection, prevent Epstein-Barr virus infection, and / or treat and / or prevent diseases caused by Epstein-Barr virus infection.

The present invention generally relates to immunogenic compositions (e.g., vaccines and immunotherapies) that induce an immune response against Epstein Barr Virus (EBV)-associated antigens. The present invention also relates to methods of use thereof for the treatment and prevention of EBV infection, EBV-associated cancer, or a combination thereof. In various embodiments, the EBV antigen comprises BamHI-A rightward frame 1 (BARF1).

The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and / or treating various health conditions associated with EBV infection.

The invention discloses a T cell receptor for specifically recognizing an HLA-A11 restricted EBV LMP2 epitope peptide and application of the T cell receptor. The invention relates to the field of biomedicine, and provides a T cell receptor for recognizing HLA-A11 restrictive LMP2373-381 epitope peptide, which comprises an alpha chain and a beta chain, the amino acid sequence of the CDR3 of the alpha chain is as shown in the 107th to 120th sites of SEQ ID NO: 2; the amino acid sequence of the CDR3 of the beta chain is as shown in 109th to 119th sites of SEQ ID NO: 4. According to the present invention, the TCR specifically recognizes and is combined with the LMP2373-381 epitope peptide / HLA-A11 compound, the corresponding TCR-T cell has the LMP2373-381 epitope peptide dependent human target cell killing ability, and the important application value is provided for the prevention and treatment of EBV infection.

The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and / or treating various health conditions associated with EBV infection.